Not exact matches
For prostate cancer patients who have rising levels of PSA (a cancer indicator) even after
radical prostatectomy, early treatment makes a difference.
For localized prostate cancer the current «gold standard» treatment is
Radical Prostatectomy (RP).
For any major decision, such as choosing a robot - assisted
radical prostatectomy, it is vital that the patient understands what will happen and commits to the decision.
The CR method is being developed
for a number of uses, such as living biobanks, personalized and regenerative medicine, and this study, using donated tissue from a 57 year - old man who underwent a
radical prostatectomy, demonstrates the first steps needed towards those goals in prostate cancer.
The present work focuses on patients with physical damage, caused by surgery (
radical prostatectomy)
for prostate cancer.
A study led by Ronald C. Chen, MD, examines quality - of - life outcomes
for modern treatment choices most patients will face, including active surveillance,
radical prostatectomy, external beam radiation treatment, and brachytherapy.
In particular, archival
radical prostatectomy tissue from patient VP62, used to generate the VP62 clone employed in nearly all downstream molecular and cellular studies of XMRV [43], was available
for analysis.